Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Long-term Buprenorphine Plasma Exposure in Subjects Who Received at Least 2 Subcutaneous (SC) Injections of Extended-release Buprenorphine (SUBLOCADE™) in Phase III Studies

NCT03752528 is registered in ClinicalTrials.gov with Indivior Inc. as lead sponsor.

NCT NCT03752528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03752528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Long-term Buprenorphine Plasma Exposure in Subjects Who Received at Least 2 Subcutaneous (SC) Injections of Extended-release Buprenorphine (SUBLOCADE™) in Phase III Studies
Lead sponsor
Indivior Inc.
Phase
Observational
Overall status
Completed
Start date
February 19, 2019
Completion date
July 18, 2019
Enrollment
53 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

opioid-use disorder